Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robin K. Minor is active.

Publication


Featured researches published by Robin K. Minor.


Cell Metabolism | 2008

Resveratrol Delays Age-Related Deterioration and Mimics Transcriptional Aspects of Dietary Restriction without Extending Life Span

Kevin J. Pearson; Joseph A. Baur; Kaitlyn N. Lewis; Leonid Peshkin; Nathan L. Price; Nazar Labinskyy; William R. Swindell; Davida Kamara; Robin K. Minor; Evelyn Perez; Hamish A. Jamieson; Yongqing Zhang; Stephen R. Dunn; Kumar Sharma; Nancy Pleshko; Laura A. Woollett; Anna Csiszar; Yuji Ikeno; David G. Le Couteur; Peter J. Elliott; Kevin G. Becker; Plácido Navas; Donald K. Ingram; Norman S. Wolf; Zoltan Ungvari; David A. Sinclair; Rafael de Cabo

A small molecule that safely mimics the ability of dietary restriction (DR) to delay age-related diseases in laboratory animals is greatly sought after. We and others have shown that resveratrol mimics effects of DR in lower organisms. In mice, we find that resveratrol induces gene expression patterns in multiple tissues that parallel those induced by DR and every-other-day feeding. Moreover, resveratrol-fed elderly mice show a marked reduction in signs of aging, including reduced albuminuria, decreased inflammation, and apoptosis in the vascular endothelium, increased aortic elasticity, greater motor coordination, reduced cataract formation, and preserved bone mineral density. However, mice fed a standard diet did not live longer when treated with resveratrol beginning at 12 months of age. Our findings indicate that resveratrol treatment has a range of beneficial effects in mice but does not increase the longevity of ad libitum-fed animals when started midlife.


Nature Communications | 2013

Metformin improves healthspan and lifespan in mice

Alejandro Martin-Montalvo; Evi M. Mercken; Sarah J. Mitchell; Hector H. Palacios; Patricia L. Mote; Morten Scheibye-Knudsen; Ana P. Gomes; Theresa M. Ward; Robin K. Minor; Marie-José Blouin; Matthias Schwab; Michael Pollak; Yongqing Zhang; Yinbing Yu; Kevin G. Becker; Vilhelm A. Bohr; Donald K. Ingram; David A. Sinclair; Norman S. Wolf; Stephen R. Spindler; Michel Bernier; Rafael de Cabo

Metformin is a drug commonly prescribed to treat patients with type 2 diabetes. Here we show that long-term treatment with metformin (0.1% w/w in diet) starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Treatment with metformin mimics some of the benefits of calorie restriction, such as improved physical performance, increased insulin sensitivity, and reduced LDL and cholesterol levels without a decrease in caloric intake. At a molecular level, metformin increases AMP-activated protein kinase activity and increases antioxidant protection, resulting in reductions in both oxidative damage accumulation and chronic inflammation. Our results indicate that these actions may contribute to the beneficial effects of metformin on healthspan and lifespan. These findings are in agreement with current epidemiological data and raise the possibility of metformin-based interventions to promote healthy aging.


Nature Reviews Drug Discovery | 2012

Are sirtuins viable targets for improving healthspan and lifespan

Joseph A. Baur; Zoltan Ungvari; Robin K. Minor; David G. Le Couteur; Rafael de Cabo

Although the increased lifespan of our populations illustrates the success of modern medicine, the risk of developing many diseases increases exponentially with old age. Caloric restriction is known to retard ageing and delay functional decline as well as the onset of disease in most organisms. Studies have implicated the sirtuins (SIRT1–SIRT7) as mediators of key effects of caloric restriction during ageing. Two unrelated molecules that have been shown to increase SIRT1 activity in some settings, resveratrol and SRT1720, are excellent protectors against metabolic stress in mammals, making SIRT1 a potentially appealing target for therapeutic interventions. This Review covers the current status and controversies surrounding the potential of sirtuins as novel pharmacological targets, with a focus on SIRT1.


Cell Reports | 2014

The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet

Sarah J. Mitchell; Alejandro Martin-Montalvo; Evi M. Mercken; Hector H. Palacios; Theresa M. Ward; Gelareh Abulwerdi; Robin K. Minor; George P. Vlasuk; James L. Ellis; David A. Sinclair; John A. Dawson; David B. Allison; Yongqing Zhang; Kevin G. Becker; Michel Bernier; Rafael de Cabo

The prevention or delay of the onset of age-related diseases prolongs survival and improves quality of life while reducing the burden on the health care system. Activation of sirtuin 1 (SIRT1), an NAD(+)-dependent deacetylase, improves metabolism and confers protection against physiological and cognitive disturbances in old age. SRT1720 is a specific SIRT1 activator that has health and lifespan benefits in adult mice fed a high-fat diet. We found extension in lifespan, delayed onset of age-related metabolic diseases, and improved general health in mice fed a standard diet after SRT1720 supplementation. Inhibition of proinflammatory gene expression in both liver and muscle of SRT1720-treated animals was noted. SRT1720 lowered the phosphorylation of NF-κB pathway regulators in vitro only when SIRT1 was functionally present. Combined with our previous work, the current study further supports the beneficial effects of SRT1720 on health across the lifespan in mice.


Scientific Reports | 2011

SRT1720 improves survival and healthspan of obese mice

Robin K. Minor; Joseph A. Baur; Ana P. Gomes; Theresa M. Ward; Anna Csiszar; Evi M. Mercken; Kotb Abdelmohsen; Yu Kyong Shin; Carles Cantó; Morten Scheibye-Knudsen; Melissa Krawczyk; Pablo M. Irusta; Alejandro Martin-Montalvo; Basil P. Hubbard; Yongqing Zhang; Elin Lehrmann; Alexa A. White; Nathan L. Price; William R. Swindell; Kevin J. Pearson; Kevin G. Becker; Vilhelm A. Bohr; Myriam Gorospe; Josephine M. Egan; Mark I. Talan; Johan Auwerx; Christoph H. Westphal; James L. Ellis; Zoltan Ungvari; George P. Vlasuk

Sirt1 is an NAD+-dependent deacetylase that extends lifespan in lower organisms and improves metabolism and delays the onset of age-related diseases in mammals. Here we show that SRT1720, a synthetic compound that was identified for its ability to activate Sirt1 in vitro, extends both mean and maximum lifespan of adult mice fed a high-fat diet. This lifespan extension is accompanied by health benefits including reduced liver steatosis, increased insulin sensitivity, enhanced locomotor activity and normalization of gene expression profiles and markers of inflammation and apoptosis, all in the absence of any observable toxicity. Using a conditional SIRT1 knockout mouse and specific gene knockdowns we show SRT1720 affects mitochondrial respiration in a Sirt1- and PGC-1α-dependent manner. These findings indicate that SRT1720 has long-term benefits and demonstrate for the first time the feasibility of designing novel molecules that are safe and effective in promoting longevity and preventing multiple age-related diseases in mammals.


Neurobiology of Aging | 2008

A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a kainate-induced learning impairment in rats

Kara B. Duffy; Edward L. Spangler; Bryan D. Devan; Zhihong Guo; Jonna L. Bowker; Anne M. Janas; Adrienne Hagepanos; Robin K. Minor; Rafael DeCabo; Peter R. Mouton; Barbara Shukitt-Hale; James A. Joseph; Donald K. Ingram

Young male Fischer-344 rats were fed a diet containing 2% blueberry (BB) extract or control diet for at least 8 weeks and then received bilateral hippocampal injections of kainic acid (KA 200 ng/0.5 microl) or phosphate buffered saline (PBS). One week later rats were trained in one-way active footshock avoidance in a straight runway followed the next day by training in a footshock motivated 14-unit T-maze with documented sensitivity to hippocampal glutamatergic manipulations. Based on analyses of several performance variables, KA-treated rats exhibited clearly impaired learning performance; however, the BB diet significantly reduced this impairment. Supporting the behavioral findings, stereological assessment of CA1 pyramidal neurons documented greater neuronal loss in KA-treated controls compared to KA-treated rats on the BB diet. In an in vitro experiment, FaO cells grown in medium supplemented with serum from BB-fed rats had enhanced viability after exposure to hydrogen peroxide. These findings suggest that BB supplementation may protect against neurodegeneration and cognitive impairment mediated by excitotoxicity and oxidative stress.


Aging Cell | 2014

SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass

Evi M. Mercken; Sarah J. Mitchell; Alejandro Martin-Montalvo; Robin K. Minor; Maria Almeida; Ana P. Gomes; Morten Scheibye-Knudsen; Hector H. Palacios; Jordan J Licata; Yongqing Zhang; Kevin G. Becker; Husam Khraiwesh; José A. González-Reyes; José M. Villalba; Joseph A. Baur; Peter J. Elliott; Christoph H. Westphal; George P. Vlasuk; James L. Ellis; David A. Sinclair; Michel Bernier; Rafael de Cabo

Increased expression of SIRT1 extends the lifespan of lower organisms and delays the onset of age‐related diseases in mammals. Here, we show that SRT2104, a synthetic small molecule activator of SIRT1, extends both mean and maximal lifespan of mice fed a standard diet. This is accompanied by improvements in health, including enhanced motor coordination, performance, bone mineral density, and insulin sensitivity associated with higher mitochondrial content and decreased inflammation. Short‐term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy. These results demonstrate it is possible to design a small molecule that can slow aging and delay multiple age‐related diseases in mammals, supporting the therapeutic potential of SIRT1 activators in humans.


Toxicology and Applied Pharmacology | 2010

Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats

Robin K. Minor; Daniel L. Smith; Alex M. Sossong; Susmita Kaushik; Suresh Poosala; Edward L. Spangler; George S. Roth; Mark A. Lane; David B. Allison; Rafael de Cabo; Donald K. Ingram; Julie A. Mattison

Calorie restriction (CR), the purposeful reduction of energy intake with maintenance of adequate micronutrient intake, is well known to extend the lifespan of laboratory animals. Compounds like 2-deoxy-D-glucose (2DG) that can recapitulate the metabolic effects of CR are of great interest for their potential to extend lifespan. 2DG treatment has been shown to have potential therapeutic benefits for treating cancer and seizures. 2DG has also recapitulated some hallmarks of the CR phenotype including reduced body temperature and circulating insulin in short-term rodent trials, but one chronic feeding study in rats found toxic effects. The present studies were performed to further explore the long-term effects of 2DG in vivo. First we demonstrate that 2DG increases mortality of male Fischer-344 rats. Increased incidence of pheochromocytoma in the adrenal medulla was also noted in the 2DG treated rats. We reconfirm the cardiotoxicity of 2DG in a 6-week follow-up study evaluating male Brown Norway rats and a natural form of 2DG in addition to again examining effects in Fischer-344 rats and the original synthetic 2DG. High levels of both 2DG sources reduced weight gain secondary to reduced food intake in both strains. Histopathological analysis of the hearts revealed increasing vacuolization of cardiac myocytes with dose, and tissue staining revealed the vacuoles were free of both glycogen and lipid. We did, however, observe higher expression of both cathepsin D and LC3 in the hearts of 2DG-treated rats which indicates an increase in autophagic flux. Although a remarkable CR-like phenotype can be reproduced with 2DG treatment, the ultimate toxicity of 2DG seriously challenges 2DG as a potential CR mimetic in mammals and also raises concerns about other therapeutic applications of the compound.


Journals of Gerontology Series A-biological Sciences and Medical Sciences | 2010

Dietary Interventions to Extend Life Span and Health Span Based on Calorie Restriction

Robin K. Minor; Joanne S. Allard; Caitlin M. Younts; Theresa M. Ward; Rafael de Cabo

The societal impact of obesity, diabetes, and other metabolic disorders continues to rise despite increasing evidence of their negative long-term consequences on health span, longevity, and aging. Unfortunately, dietary management and exercise frequently fail as remedies, underscoring the need for the development of alternative interventions to successfully treat metabolic disorders and enhance life span and health span. Using calorie restriction (CR)-which is well known to improve both health and longevity in controlled studies-as their benchmark, gerontologists are coming closer to identifying dietary and pharmacological therapies that may be applicable to aging humans. This review covers some of the more promising interventions targeted to affect pathways implicated in the aging process as well as variations on classical CR that may be better suited to human adaptation.


Ageing Research Reviews | 2006

Bioenergetics of aging and calorie restriction

Nicole D. Hunt; Dong Hoon Hyun; Joanne S. Allard; Robin K. Minor; Mark P. Mattson; Donald K. Ingram; Rafael de Cabo

Aging is a physiological process that involves a multi-factorial set of deleterious changes. These alterations are caused by an exponential increase in damage to macromolecules. This process is likely due to the cumulative effects of oxidative stress over time. One area of ongoing research in gerontology has focused on determining why there is an age-dependent decrease in cellular bioenergetics. The aim of this review is to summarize the recent findings on the effects of aging and calorie restriction on energy metabolism. The effect of calorie restriction on age-associated changes in bioenergetic parameters will be examined.

Collaboration


Dive into the Robin K. Minor's collaboration.

Top Co-Authors

Avatar

Rafael de Cabo

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kevin G. Becker

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yongqing Zhang

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Donald K. Ingram

Pennington Biomedical Research Center

View shared research outputs
Top Co-Authors

Avatar

Evi M. Mercken

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph A. Baur

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Theresa M. Ward

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge